Read the gaps as well as the hopes

Make room for what is unknown.

Read what is missing as carefully as what is claimed. Then bring the gaps into the conversation.

FDA is short for the Food and Drug Administration, which reviews medicines in the US.

The short answer

As of September 2026, Selank’s safety has not been established by large, long human studies.

As of September 2026, the FDA says key information about possible human harm is missing.

The FDA’s Selank entry warns that the body may react to the drug as an invader with some ways of giving it.

The entry does not say which ways it means, so it does not tell us whether this concern applies to nose drops, injections, or both.

An immune reaction means the body may treat the substance as an invader.

FDA links this concern to peptide clumps and impurities, which are unwanted material.

This is a concern about possible harm, not proof that a particular product is contaminated.

A short list of reported effects cannot stand in for a full picture of harm.

The Russian maker’s leaflet lists unpleasant taste and allergic reactions; it gives no rates for either.

As of September 2026, that leaflet rules out use during pregnancy, while breastfeeding, and by people under 18.

It also rules out use by people who react badly to the product.

The leaflet’s limits are not a complete FDA-reviewed safety list.

The Russian leaflet says Selank can be taken with medicines that affect the brain, including medicines used for calming or mood problems.

Yet laboratory work found that Selank can change how some of those medicines act, including diazepam and olanzapine.

It is not known how these combinations affect people, so the leaflet’s statement does not settle whether a combination could cause harm.

Questions to raise with the health professional

Write below, or use paper. Copy anything worth keeping; the page does not save your notes.

Could Selank change how any of my current medicines work?What personal circumstances need discussing?What would need prompt attention?

Government Selank entryThe FDA identifies a gap.Open the evidence note

The FDA page still shows the Selank safety concern beside the withdrawn request and gives April 22, 2026 as its “current as of” date.

As of September 2026, taking back that request did not mean the FDA had cleared Selank of that concern.

FDA reporting programmeA problem can be reported.Open the evidence note

MedWatch is the FDA’s free route for patients to report a problem with a medicine.

A submitted report alone does not prove which medicine caused a problem.